Neulasta: payments to doctors
Payments that named Neulasta as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $534K
- Providers
- 4,180
- Transactions
- 11,514
- Average per transaction
- $46
The per-transaction average — $46 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,180 providers the average total is $128, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Amgen | $521,809 | 97.7% |
| Amneal Pharmaceuticals LLC | $12,297 | 2.3% |